Endologix Inc. (NASDAQ:ELGX) currently has a “Sell” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Sell” signal. 10 – 8 Day Moving Average Hilo Channel shows “Sell” signal. While 20-Day Moving Average VS Current Price shows “Sell” Signal.
Endologix Inc. (NASDAQ:ELGX) lost -6.19 Percent and closed its previous trading session at $3.79. The stock traded with the average Volume of 563.53 Million at the end of last session.
Endologix Inc. (NASDAQ:ELGX) has the Market Capitalization of 313.21 Million. The Stock has its 52-week High of $7.66 and 52-Week Low of $3.77 and it touched its 52-week high on 05/01/17 and 52-Week Low on 02/14/18.
The company reported its last earnings Actual EPS of $-0.11/share. While, the analyst predicted that the company could provide an EPS of $-0.17/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.06/share which shows an Earnings Surprise of 35.3 Percent.
Sell side analysts plays vital role in buying and selling a stock where 0 analysts rated Endologix Inc. (NASDAQ:ELGX) as Buy, 0 analysts given Outperform signal, 3 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -10.35% where SMA50 and SMA200 are -20.36% and -23.74% respectively.
The company shows its Return on Assets (ROA) value of -20.7%. The Return on Equity (ROE) value stands at -78.8%. While it’s Return on Investment (ROI) value is -32.1%.
Endologix Inc. (NASDAQ:ELGX) currently has a Weekly Volatility of 5.06% percent while its Monthly Volatility is at 4.09% percent. While talking about Performance of the Stock, Endologix Inc. currently has a Weekly performance of -8.67%, monthly performance percentage is -10.82 percent, Quarterly performance is -22.02 percent, 6 months performance shows a percent value of -11.96% and Yearly Performance is -44.02 percent.
Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis.